- Home
- RITM vs TGTX Comparison
RITM vs TGTX Comparison
Compare RITM & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RITM
- TGTX
- Stock Information
- Founded
- RITM 2011
- TGTX 1993
- Country
- RITM United States
- TGTX United States
- Employees
- RITM N/A
- TGTX N/A
- Industry
- RITM Real Estate Investment Trusts
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- RITM Real Estate
- TGTX Health Care
- Exchange
- RITM Nasdaq
- TGTX Nasdaq
- Market Cap
- RITM 6.1B
- TGTX 5.5B
- IPO Year
- RITM N/A
- TGTX 1995
- Fundamental
- Price
- RITM $10.89
- TGTX $33.42
- Analyst Decision
- RITM Strong Buy
- TGTX Strong Buy
- Analyst Count
- RITM 8
- TGTX 6
- Target Price
- RITM $14.25
- TGTX $47.50
- AVG Volume (30 Days)
- RITM 6.2M
- TGTX 1.5M
- Earning Date
- RITM 10-30-2025
- TGTX 11-04-2025
- Dividend Yield
- RITM 9.21%
- TGTX N/A
- EPS Growth
- RITM 9.18
- TGTX N/A
- EPS
- RITM 1.30
- TGTX 0.36
- Revenue
- RITM $3,665,023,000.00
- TGTX $454,069,000.00
- Revenue This Year
- RITM N/A
- TGTX $82.13
- Revenue Next Year
- RITM $4.75
- TGTX $49.01
- P/E Ratio
- RITM $8.33
- TGTX $92.40
- Revenue Growth
- RITM 16.59
- TGTX 30.96
- 52 Week Low
- RITM $9.13
- TGTX $22.61
- 52 Week High
- RITM $12.74
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- RITM 39.34
- TGTX 46.74
- Support Level
- RITM $10.78
- TGTX $34.01
- Resistance Level
- RITM $11.08
- TGTX $35.52
- Average True Range (ATR)
- RITM 0.16
- TGTX 1.28
- MACD
- RITM 0.04
- TGTX -0.30
- Stochastic Oscillator
- RITM 58.24
- TGTX 14.12
About RITM Rithm Capital Corp.
Rithm Capital Corp operates as a real estate investment trust that provides capital and services to the real estate and financial services industries. The company aims to generate attractive risk-adjusted returns in all interest-rate environments through a complementary portfolio of investments and operating businesses. Its investment portfolio is composed of mortgage servicing-related assets (full and excess MSRs and servicer advances), residential securities (and associated call rights) loans (including single-family rental), and consumer loans. Its operating segments are Origination and Servicing; Investment Portfolio; Residential Transitional Lending; and Asset Management.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.